MEdPACTO

Dr. John Letterio is an interim Director of UH Seidman Cancer Center at Cleveland Medical Center and a Division Chief at the Cancer Research Center at UH Rainbow Babies and Children’s Hospital, Case Western Reserve University (UH BR&C).

He has been researching TGF-β agonists in immune disorder for a long time with CEO SeongJin Kim, CEO of MedPacto.

Dr. John Letterio was the first to map out and develop bi-dentate inhibitor of Cdk5 and also had defined CDK5 roles as Modulators of tumor therapeutics and immune checkpoint regulatory molecules.

Dr. Isaac Kim is currently serving as a Professor Urology and the head of the department at Yale University School of Medicine.

He has extensive clinical experience in urological oncology including androgen signaling of prostate cancer in the tumor microenvironment, Dr. Kim is currently practicing a clinical trial for bone metastasis of urinary cancer.

Dr. Hyun Bae, MD is a distinguished spine fellowship and trained board-certified orthopedic surgeon practicing at Spine-center at Cedars-Sinai Medical Center and the Spine Institute in Santa Monica CA.

His specialties lie in the repair of In Vitro Diagnostics (IVD) and evaluating instrumentation for spinal fusion and grafting materials. Dr. Bae has written or co-authored more than 70 published scientific papers and has around 30 patents.

Dr. Greg Licholai, MD is the Chief Medical & Innovation Officer at ICON plc., Co-Director of Digital Health Center, and Professor at Yale School of Management, teaches Healthcare Innovation at Harvard Business School.

He had previously served as the President of rare diseases at Moderna Therapeutics, President and Chief Medical Officer at Castle Creek Pharmaceuticals and partner at McKinsey & Co. where he ran the healthcare data service line.